This content is machine translated COVID-19 in hematologic patients. Lessons learned from the pandemic The SARS-CoV-2 virus poses a particular challenge for hematologic patients. hazard. On the one hand, their immune system is often weakened by the disease and, on the other hand, numerous therapies…
View Post 5 min This content is machine translated Iron deficiency Classify laboratory parameters correctly Iron is a trace element that is mainly involved in oxygen transport and blood formation in the body. Both iron deficiency and iron excess can severely disrupt the organism and…
View Post 5 min This content is machine translated Immunotherapy Untapped potential in early disease stages Over the last decade, immunotherapy using checkpoint inhibitors has become established in the treatment of many oncological conditions. Especially in advanced tumor disease, ipilimumab, nivolumab and co. play a significant…
View Post 5 min This content is machine translated Venous thromboembolism Clinical assessment and anticoagulant therapy – an update. If thromboembolism is not detected and treated in time, life-threatening consequences may result. Validated tests, such as the Wells score and the D-dimer test, can be used to assess the…
View Post 4 min This content is machine translated Acute myeloid leukemia (AML) “A new standard of care for elderly and fragile patients” A BCL-2 inhibitor is convincing in new studies in the first-line treatment of AML patients who are not suitable for intensive chemotherapy [1]. Hematologists Dr. Georgios Georgiou and Prof. Photis…
View Post 5 min This content is machine translated Paroxysmal nocturnal hemoglobinuria (PNH) From iron deficiency to diagnosis Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disease characterized by intravascular hemolysis and hemoglobinuria. Due to a prolonged loss of hemoglobin through the urine, PNH can lead to iron…
View Post 5 min This content is machine translated Multiple Myeloma Focus on first-line therapy The innovation of recent years has long since found its way into first-line therapy in multiple myeloma. Thus, the EHA-ESMO Guidelines were amended accordingly in January. Daratumumab, a monoclonal antibody…
View Post 6 min This content is machine translated CAR-T cell therapy Paving the way to success With the increasing clinical application of CAR-T cells, the practical aspects of therapy are a growing concern. Which patients should receive treatment using CAR-T cells outside of clinical trials? What…
View Post 4 min This content is machine translated Hodgkin's disease Excess mortality after surviving disease: a search for causes Today, more than 80% of all patients with Hodgkin lymphoma can be cured, and in early stages even more than 90%. Nevertheless, the disease and its therapy have a significant…
View Post 3 min This content is machine translated Monoclonal Gammopathy of Unclear Significance (MGUS) Identification of patients at risk Patients with monoclonal gammopathy of uncertain significance (MGUS) are at increased risk of developing certain forms of cancer. Regular checks allow changes to be detected at an early stage and…
View Post 2 min This content is machine translated Leukemic cutaneous T-cell lymphoma (L-CTCL) Sézary syndrome and mycosis fungoides: STAT5 as a therapeutic target? As the disease progresses, the tumor cells in leukemic variants of cutaneous T-cell lymphomas spread not only in the skin but also in the blood and lymph nodes. Although an…
